Standard BioTools (LAB) announced the strategic sale of SomaLogic to Illumina (ILMN), including SomaScan Assay Services, Authorized Sites and KREX for an upfront payment of $350 million in cash at closing and up to $75 million in cash in near-term milestone payments, for aggregate cash consideration of up to $425 million, plus specified sales royalties on SOMAmer-based next-generation sequencing library preparation kits. Standard BioTools will retain certain Single SOMAmer reagent commercialization rights.
Standard BioTools said the deal significantly simplifies the operating structure of the company and enables the achievement of adjusted EBITDA break-even.
Shares of Standard BioTools are up 20% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.